The Effectiveness of Sofosbuvir and Daclatasvir in the Treatment of Hepatitis C in Thalassaemia Major Patients and their Effect on Haematological Factors-Reference-Cited by-同舟云学术

The Effectiveness of Sofosbuvir and Daclatasvir in the Treatment of Hepatitis C in Thalassaemia Major Patients and their Effect on Haematological Factors

Published:2018-04 Issue:2 Volume:36 Page:224-229
ISSN:0255-0857
Container-title:Indian Journal of Medical Microbiology
language:en
Short-container-title:Indian Journal of Medical Microbiology

Author:

Zamani Farhad,Ajdarkosh Hossein,Safarnezhad-Tameshkel Fahimeh,Azarkeivan Azita,Keyvani Hossein,Naserifar Farshad,Vafaeimanesh Jamshid

Publisher

Elsevier BV

Subject

Microbiology (medical)

Reference31 articles.

1. WHO guidelines on testing for hepatitis B and C – Meeting targets for testing;Hellard;BMC Infect Dis,2017

2. Distribution of hepatitis C virus genotypes in Rasht, capital city of Guilan province, Northern part of Iran;Naghipour-Khalkhaliani;Hepat Mon,2018

3. Trend in prevalence of hepatitis C virus infection among β-thalassemia major patients: 10 years of experience in Iran;Jafroodi;Int J Prev Med,2015

4. Frequency of thalassemia in Iran and Khorasan Razavi;Khodaei;Int J Pediatr,2013

5. Blood transfusion transmitted infections in multiple blood transfused patients of beta thalassaemia;Vidja;Indian J Hematol Blood Transfus,2011

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-Term Follow-Up of Thalassemia Major Patients with Hepatitis C Virus Treated with Sofosbuvir and Daclatasvir: A Cohort Study;Archives of Medical Research;2022-11

2. Challenges of Hepatitis C Virus Treatment in Thalassemia;Blood - Updates on Hemodynamics and Thalassemia;2022-03-16

3. Sofosbuvir/Ledipasvir for Treatment of Chronic Hepatitis C Infection in Adult Patients with β- Thalassemia Major: A Real-Life Study;Endocrine, Metabolic & Immune Disorders - Drug Targets;2021-02-02

4. EASL recommendations on treatment of hepatitis C: Final update of the series☆;Journal of Hepatology;2020-11

5. 2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations;Journal of the Formosan Medical Association;2020-07